Physician Views snap poll - What scope for oral competition to Dupixent?

The success of Sanofi and Regeneron Pharmaceuticals' Dupixent as a practice-changing treatment for moderate-to-severe atopic dermatitis has spiked the interest of other drug developers.

While Dupixent is quickly becoming established as a new standard of care, a number of companies believe there is considerable opportunity for oral competitors to emerge (Dupixent is a monoclonal antibody administered by subcutaneous injection).

Earlier this month, Pfizer announced positive top-line data for its JAK inhibitor abrocitinib; a treatment that it believes may offer a faster onset of action than Dupixent.

To get a better understanding of what opportunity could exist for new therapies like abrocitinib, we are snap-polling US and EU3 (France, Germany and the UK) based dermatologists who have prescribed Dupixent with the following questions… 

How would you rate your satisfaction/the satisfaction of your patients with Dupixent (dupilumab) as a treatment for moderate-to-severe atopic dermatitis?

Not at all satisfied

Slightly satisfied

Somewhat satisfied

Moderately satisfied

Extremely satisfied

________

Approximately what percentage of patients treated with Dupixent for moderate-to-severe atopic dermatitis do not respond to therapy and would ideally need to use an alternative treatment?

________

How frequently does the need to administer Dupixent by subcutaneous injection preclude patients from using it or require them to abandon therapy?

Never

Rarely

Occasionally

Often

Always

________

It has just been announced that a new oral JAK1 inhibitor - abrocitinib - met its primary and secondary endpoints in a pivotal-stage study, though data has yet to be released.

As a potential future treatment option, how compelling would an oral therapy offering similar efficacy to Dupixent and a clean safety profile be for your patients?

Not at all compelling

Slightly compelling

Somewhat compelling

Moderately compelling

Extremely compelling

________

Let's assume that oral therapies for moderate-to-severe atopic dermatitis reach the market, but are not as efficacious as Dupixent.

To what extent would you be willing to sacrifice efficacy to use an oral therapy?

Not willing to sacrifice efficacy

Slightly willing

Somewhat willing

Moderately willing

Extremely willing

________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.